Table 6.
Number of TAND studies according to country (and study type)
| Countries | Total (A, CS, CO) | Countries | Total (A, CS, CO) | Countries | Total (A, CS, CO) | Countries | Total (A, CS, CO) | Countries (S-U) | Total (A, CS, CO) |
|---|---|---|---|---|---|---|---|---|---|
| Argentina | 1 (0, 0, 1) | Denmark | 4 (0, 0, 4) | Israel | 3 (0, 0, 3) | Norway | 4 (0, 0, 4) | South Africa | 5 (0, 0, 5) |
| Australia | 9 (2, 0, 7) | Egypt | 1 (0, 0, 1) | Italy | 18 (1, 1, 16) | Oman | 2 (0, 2, 0) | South Korea | 8 (0, 2, 6) |
| Austria | 4 (0, 0, 4) | Estonia | 3 (0, 0, 3) | Japan | 10 (1, 3, 6) | Pakistan | 1 (0, 1, 0) | Spain | 6 (0, 0, 6) |
| Belgium | 6 (0, 0, 6) | France | 9 (0, 2, 7) | Latvia | 3 (0, 0, 3) | Poland | 10 (0, 1, 9) | Sweden | 5 (0, 0, 5) |
| Canada | 7 (2, 0, 5) | Germany | 14 (6, 0, 8) | Lithuania | 3 (0, 0, 3) | Portugal | 4 (0, 0, 4) | Taiwan | 6 (0, 0, 6) |
| China | 10 (0, 1, 9) | Greece | 4 (0, 0, 4) | Malaysia | 1 (0, 0, 1) | Romania | 3 (0, 0, 3) | Thailand | 4 (0, 0, 4) |
| Colombia | 1 (0, 0, 1) | Hungary | 1 (0, 0, 1) | Mexico | 1 (0, 0, 1) | Russia | 4 (0, 0, 4) | Turkey | 4 (0, 0, 4) |
| Croatia | 1 (0, 1, 0) | India | 9 (0, 9, 0) | Netherlands | 14 (0, 1, 13) | Slovakia | 3 (0, 0, 3) | UK | 50 (0, 5, 45) |
| Czech Republic | 5 (0, 0, 5) | Ireland | 1 (0, 0, 1) | New Zealand | 1 (0, 1, 0) | Slovenia | 3 (0, 0, 3) | USA | 89 (21, 12, 56) |
Countries listed in alphabetical order. A animal studies, CS case studies, CO cohort studies. Three hundred forty-one individual research sites across 230 studies depicted according to country, as multisite large-scale registry studies are also represented (e.g. Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy—Tuberous Sclerosis Complex (EPISTOP) and TuberOus SClerosis registry to increase disease Awareness (TOSCA)). Please note that specific European countries described in one study as ‘other European countries’ are not represented [90]